Ignite Creation Date:
2024-05-11 @ 8:31 AM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06400472
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-04-30
Brief Title:
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A First-in-Human Phase 1a1b Trial to Assess the Safety Tolerability and Preliminary Efficacy of LY4170156 an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells in Participants With Selected Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to find out whether the study drug LY4170156 is safe tolerable and effective in participants with advanced solid tumors The study is conducted in two parts - phase Ia dose-escalation dose-optimization and phase Ib dose-expansion The study will last up to approximately 4 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2024-511238-11-00 | CTIS | None | None |
| J5E-OX-JZXA | OTHER | Eli Lilly and Company | None |